Volasertib preclinical activity in high-risk hepatoblastoma.

التفاصيل البيبلوغرافية
العنوان:	Volasertib preclinical activity in high-risk hepatoblastoma.
المؤلفون:	Kats D; Children's Cancer Therapy Development Institute, Beaverton, OR, USA., Ricker CA; Children's Cancer Therapy Development Institute, Beaverton, OR, USA., Berlow NE; Children's Cancer Therapy Development Institute, Beaverton, OR, USA., Noblet B; Research and Development Unit, XenTech, Evry, France., Nicolle D; Research and Development Unit, XenTech, Evry, France., Mevel K; Research and Development Unit, XenTech, Evry, France., Branchereau S; Bicêtre Hospital, Le Kremlin Bicêtre, France., Judde JG; Research and Development Unit, XenTech, Evry, France., Stiverson CD; Children's Cancer Therapy Development Institute, Beaverton, OR, USA., Stiverson CL; Children's Cancer Therapy Development Institute, Beaverton, OR, USA., Svalina MN; Children's Cancer Therapy Development Institute, Beaverton, OR, USA., Settelmeyer T; Children's Cancer Therapy Development Institute, Beaverton, OR, USA., Matlock K; Omics Data Automation, Beaverton, OR, USA., Lathara M; Omics Data Automation, Beaverton, OR, USA., Mussini C; Research and Development Unit, XenTech, Evry, France., Geller JI; Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA., Noakes C; Champions Oncology, Rockville, MD, USA., Sloma I; Champions Oncology, Rockville, MD, USA., Bharathy N; Children's Cancer Therapy Development Institute, Beaverton, OR, USA., Cairo S; Research and Development Unit, XenTech, Evry, France., Keller C; Children's Cancer Therapy Development Institute, Beaverton, OR, USA.
المصدر:	Oncotarget [Oncotarget] 2019 Nov 05; Vol. 10 (60), pp. 6403-6417. Date of Electronic Publication: 2019 Nov 05 (Print Publication: 2019).
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
أسماء مطبوعة:	Original Publication: Albany, N.Y. : Impact Journals
مستخلص:	Relapsed and metastatic hepatoblastoma represents an unmet clinical need with limited chemotherapy treatment options. In a chemical screen, we identified volasertib as an agent with in vitro activity, inhibiting hepatoblastoma cell growth while sparing normal hepatocytes. Volasertib targets PLK1 and prevents the progression of mitosis, resulting in eventual cell death. PLK1 is overexpressed in hepatoblastoma biopsies relative to normal liver tissue. As a potential therapeutic strategy, we tested the combination of volasertib and the relapse-related hepatoblastoma chemotherapeutic irinotecan. We found both in vitro and in vivo efficacy of this combination, which may merit further preclinical investigation and exploration for a clinical trial concept. Competing Interests: CONFLICTS OF INTEREST The authors have no conflicts of interest with respect to the drugs used in this study. (Copyright: Kats et al.)
References:	Oncoimmunology. 2013 Jan 1;2(1):e22620. (PMID: 23482411) Transl Oncol. 2015 Jun;8(3):185-95. (PMID: 26055176) Cancer Sci. 2015 Nov;106(11):1590-5. (PMID: 26471242) Hepatology. 2016 Oct;64(4):1121-35. (PMID: 27115099) Acta Pharmacol Sin. 2012 Jun;33(6):852-8. (PMID: 22669119) Biochim Biophys Acta. 2013 Jan;1835(1):11-27. (PMID: 23006513) Nat Rev Cancer. 2006 Oct;6(10):789-802. (PMID: 16990856) Sci Rep. 2016 Dec 02;6:38347. (PMID: 27910913) World J Transplant. 2014 Dec 24;4(4):294-8. (PMID: 25540737) Oncol Rep. 2019 Jan;41(1):143-153. (PMID: 30320362) Cancer Cell. 2008 Dec 9;14(6):471-84. (PMID: 19061838) Hum Pathol. 2009 Oct;40(10):1512-5. (PMID: 19751877) Mol Cancer Ther. 2009 Nov;8(11):3024-35. (PMID: 19887553) Nucleic Acids Res. 2012 May;40(10):4288-97. (PMID: 22287627) Br J Cancer. 2014 May 13;110(10):2434-40. (PMID: 24755882) Anticancer Res. 2016 Nov;36(11):5577-5592. (PMID: 27793881) Onco Targets Ther. 2015 Jul 17;8:1761-71. (PMID: 26229484) Invest New Drugs. 2015 Jun;33(3):611-20. (PMID: 25794535) J Clin Oncol. 2012 Apr 1;30(10):1042-9. (PMID: 22370326) J Pediatr Surg. 2001 May;36(5):755-9. (PMID: 11329582) Oncogene. 2004 Aug 5;23(35):5901-11. (PMID: 15221005) Pediatr Hematol Oncol. 2015 Feb;32(1):18-25. (PMID: 24852330) Nat Rev Mol Cell Biol. 2014 Jul;15(7):433-52. (PMID: 24954208) Oncotarget. 2018 Apr 27;9(32):22665-22679. (PMID: 29854306) Am J Cancer Res. 2016 Nov 01;6(11):2476-2488. (PMID: 27904765) Oncotarget. 2017 Jul 26;8(45):78452-78465. (PMID: 29108241) J Pharmacol Exp Ther. 2015 Mar;352(3):579-89. (PMID: 25576074) Cancer Lett. 2019 Mar 31;445:24-33. (PMID: 30611741) Leukemia. 2015 Jan;29(1):11-9. (PMID: 25027517) Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1725-30. (PMID: 19181852) Molecules. 2015 Apr 08;20(4):6113-27. (PMID: 25856061) J Clin Oncol. 2007 Oct 10;25(29):4622-7. (PMID: 17925558) Eur J Cancer. 2012 Dec;48(18):3456-64. (PMID: 22835780) Mol Cancer Ther. 2016 Jul;15(7):1427-35. (PMID: 27330107) Oncotarget. 2018 Jan 8;9(12):10497-10509. (PMID: 29535822) Pediatr Blood Cancer. 2012 Nov;59(5):776-9. (PMID: 22692949) Ann Oncol. 2001 Nov;12(11):1631-41. (PMID: 11822765) J Cell Sci. 1994 Jun;107 ( Pt 6):1509-17. (PMID: 7962193) J Pediatr Hematol Oncol. 2011 Aug;33(6):e226-30. (PMID: 21792028) Clin Cancer Res. 2009 May 1;15(9):3094-102. (PMID: 19383823) Hepatology. 2017 Jan;65(1):104-121. (PMID: 27775819) Hepatology. 2018 Jul;68(1):89-102. (PMID: 29152775) Br J Cancer. 2003 Nov 17;89(10):1849-54. (PMID: 14612891) Biomark Res. 2018 Oct 30;6:31. (PMID: 30450210) Oncotarget. 2015 Apr 20;6(11):8736-49. (PMID: 25826089) Mol Oncol. 2015 Jan;9(1):140-54. (PMID: 25169932) Biochim Biophys Acta. 2010 Dec;1806(2):240-50. (PMID: 20600630)
فهرسة مساهمة:	Keywords: PLK1; cell cycle; hepatoblastoma; liver; volasertib
تواريخ الأحداث:	Date Created: 20191120 Latest Revision: 20191121
رمز التحديث:	20240628
مُعرف محوري في PubMed:	PMC6849653
DOI:	10.18632/oncotarget.27237
PMID:	31741706
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	1949-2553
DOI:	10.18632/oncotarget.27237